The study was concerned with the patients diagnosed with migraine according to the International Headache Society criteria. The treatment was initiated to the patient with a dose of 50 mg/ day for a period of 10 days, and the dose was titrated to 100 mg/ day for a period of 6 months. The adverse effects experienced by the patient's owing to the therapy were monitored every month. The rise in intra-ocular pressure (IOP) was given crucial importance and monitored using Schiotz tonometer. The paired 't'-test was used for statistical analysis using SPSS (V-11.0). Values of P 0.05 were taken to be significant.
In this study, the safety and tolerability of the medication was assessed among the 31 (29 female and 2 male) patients who were diagnosed as migraine for the first time. The mean age of the study population was found to be 27.45 AE 4.2. Of the study population, 11 patients were diagnosed as migraine with aura and 20 patients as migraine without aura. All the patients included in the study were literate and their demographics are illustrated in Table 1 .
The study patients' weight was monitored at the initial visit and their body mass index (BMI) was calculated and the average BMI was found to be 29.26 and hence were prescribed with topiramate, as this drug has been studied in obesity to induce weight reduction. 7 Among the diverse adverse drug reactions of the drug, the effects described by the patients were dizziness, somnolence, and weight loss. Among the study population (n ¼ 31), 25 patients reported the adverse drug reaction, of which 10 patients reported weight loss, somnolence, and dizziness were reported by 5 and 6 
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WEIGHT LOSS DIZZINESS SOMNOLENCE PARESTHESIAS ITCHING patients, respectively. Four patients in the study group reported paresthesias (n ¼ 3) and itching (n ¼ 1) and were discontinued from the treatment, and started with conventional therapy (Fig. 1) . Six patients did not report any adverse drug reaction and responded well to the treatment. The IOP of the patient was monitored bilaterally at each visit and it was noted that there was a significant (P 0.01) increase in the IOP from 15.72 AE 1.87 (right eye) and 15.63 AE 1.86 (left eye) at baseline to 17.47 AE 0.83 (right eye) and 17.02 AE 0.77 in the left eye at final visit (Fig. 2) .
This study categorized the various adverse effects of topiramate in migraine patients. Further studies are warranted to evaluate the safety of topiramate for prophylaxis of migraine in patients' refractory to multiple therapies.
In conclusion, topiramate, an antiepileptic drug used in the prophylactic management of migraine though appears to contribute to the reduction in migraine frequency, also produces various treatment-emergent adverse drug reactions, which need to be given supreme importance. Neurologists, ophthalmologists, and clinical pharmacists should work collectively in improving the quality of life of patients. 
